Compare BSL & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSL | PYXS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.3M | 141.3M |
| IPO Year | N/A | 2021 |
| Metric | BSL | PYXS |
|---|---|---|
| Price | $12.91 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 38.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.55% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.45 | $0.97 |
| 52 Week High | $14.35 | $5.55 |
| Indicator | BSL | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 56.61 |
| Support Level | $12.83 | $1.22 |
| Resistance Level | $13.00 | $2.92 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.70 | 48.37 |
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.